Trial reportInvestigational new drugs2003
Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.
Trial report in Investigational new drugs, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 87 citations in OpenAlex.
- A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma.International journal of clinical oncology · 2011Trial
- Article
- Systemic therapy for advanced renal cell carcinoma.Therapeutic advances in medical oncology · 2009Article
- Targeted therapies for renal cell carcinoma: more gains from using them again.Current oncology (Toronto, Ont.) · 2009Article
- The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology.Experimental cell research · 2009Review
- Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.European urology · 2008Article
- Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma.Expert opinion on drug discovery · 2008Article
- The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells.Journal of cancer research and clinical oncology · 2006Article
- VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.Current oncology reports · 2006Review
- Targeted anti-cancer therapies for renal cancer.Drugs · 2006Review
- Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.Current urology reports · 2006Article
- Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art.Drugs · 2006Review
- EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients.Pharmaceutical research · 2005Article
- Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma.British journal of cancer · 2005Article
- Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.Current oncology reports · 2005Review
- Epidermal growth factor receptor expression in renal cell carcinoma: rationale for therapy with sidling blockade.Current oncology reports · 2005Article
- Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near future.Indian journal of urology : IJU : journal of the Urological Society of IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eighteen patients with advanced renal cell carcinoma (RCC) were treated on a phase II trial with ZD1839 (IRESSA). Treatment efficacy was determined using the endpoint of improvement in time to progression (TTP) compared to TTP in patients who received interferon-alpha therapy. The Memorial Sloan Kettering Cancer Center database of renal cell patients shows that patients receiving therapy with interferon-alpha had a median TTP of 4.7 months, with 40% of patients having disease progression at 4 months. To show efficacy in this trial, 60% of evaluable patients would have to remain progression free at 4 months. Treatment with ZD1839 did not result in any complete or partial responses, and 13 patients (81%) had progression of disease within 4 months of start of therapy. At the dose and schedule used in this trial, the lack of antitumor activity associated with ZD1839 does not support further study in patients with metastatic RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.